EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Current and future management of chronic spontaneous urticaria and chronic inducible urticaria

Toan T Do, Ethan A Canty, Shyam R Joshi

Allergy and Asthma Proceedings · 2023

DOI: 10.2500/aap.2023.44.220093 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Allergy and Asthma Proceedings, 2023. Verfasst von Toan T Do und 2 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Internal Medicine, Oregon Health and Science University, Portland, Oregon. Hauptthemen laut MEDLINE: Anti-Allergic Agents, Chronic Urticaria, Histamine H1 Antagonists, Non-Sedating, Urticaria. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 110 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic urticaria (CU), characterized by ≥6 weeks of intense pruritus, remains a debilitating condition for patients. New and safe treatments are needed to manage CU recalcitrant to standard therapy.

Objective

A review of the current literature of standard and novel therapeutics in the management of CU was conducted.

Methods

A literature search via a medical literature data base and clinical trial data base was conducted to identify treatment options for CU and current clinical trials.

Results

Second-generation antihistamines, omalizumab, and cyclosporine remain the most proven therapeutic options for CU. Dupilumab, mepolizumab, benralizumab, tezepelumab, and CDX-0159 are all undergoing clinical trials for CU. Although ligelizumab demonstrated initial promising results, a phase III study was discontinued due to a nonsuperior clinical impact compared with omalizumab.

Conclusion

Novel therapies are needed for the treatment of recalcitrant CU. With a deeper understanding of the pathophysiology of CU, promising therapeutics are in clinical trials for CU.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Allergic AgentsChronic UrticariaHistamine H1 Antagonists, Non-SedatingUrticariaHumansChronic DiseaseChronic Inducible UrticariaOmalizumabClinical Trials, Phase III as TopicClinical Trials as Topic

Substanzen

Anti-Allergic AgentsHistamine H1 Antagonists, Non-SedatingOmalizumab

Autor:innen und Institutionen

  • From the Department of Internal Medicine, Oregon Health and Science University, Portland, Oregon.
  • Department of Pediatrics, Oregon Health and Science University, Portland, Oregon, and.
  • Section of Allergy and Clinical Immunology, Oregon Health and Science University, Portland, Oregon.

Zitieren

APA

Do, T. T., Canty, E. A., & Joshi, S. R. (2023). Current and future management of chronic spontaneous urticaria and chronic inducible urticaria. Allergy and Asthma Proceedings. https://doi.org/10.2500/aap.2023.44.220093

Vancouver

Do TT, Canty EA, Joshi SR. Current and future management of chronic spontaneous urticaria and chronic inducible urticaria. Allergy and Asthma Proceedings. 2023. doi:10.2500/aap.2023.44.220093

BibTeX
@article{Do2023,
  author = {Do, Toan T and Canty, Ethan A and Joshi, Shyam R},
  title = {Current and future management of chronic spontaneous urticaria and chronic inducible urticaria},
  journal = {Allergy and Asthma Proceedings},
  year = {2023},
  doi = {10.2500/aap.2023.44.220093}
}
Kostenlos starten →